(PRCT) PROCEPT BioRobotics Corporation Business Model Canvas Research

PROCEPT BioRobotics Corporation uses international distributors and commercial partners to sell AquaBeam systems outside the United States, giving it local market access, logistics, and customer support without building a full owned sales team in every country. This matters as the company scales overseas while keeping fixed costs lower.

• Local market access
• Import and logistics support
• Customer service coverage
• Lower overseas overhead

Coverage and reimbursement are a key adoption gate for Aquablation therapy: Medicare and commercial payers shape hospital buy-in because BPH care is procedure-driven, so a clear payment path lowers capex friction for PROCEPT BioRobotics Corporation systems.

• Medicare coverage speeds hospital adoption.
• Commercial insurer support widens access.
• Reimbursement cuts capital-purchase resistance.

Commercial teams place Aquablation systems in hospitals and ambulatory centers, then clinical specialists complete installation and train surgeons and staff before the first case. This makes onboarding a gating step in revenue conversion, because procedures cannot start until the system is live and the team is certified.

• System placement drives future procedure volume
• Training covers Aquablation workflow use
• Installation must finish before first surgery

PROCEPT BioRobotics Corporation must keep device clearances, technical files, and compliance current, because surgical robotics and urology systems face ongoing FDA and global post-market controls. In 2024, the Company reported $69.2 million in revenue, so its regulatory work directly supports commercialization and patient safety after launch.

• Tracks safety and performance after launch
• Maintains clearances and compliance files
• Supports mandatory post-market surveillance

Direct commercial and clinical support teams are a core resource for PROCEPT BioRobotics Corporation because the AQUABEAM system is procedure-based: field staff sell, install, train, and service the platform, then help hospitals keep cases running smoothly. That support is what drives adoption and repeat use across the installed base.

• Sell and install systems
• Train surgeons and staff
• Service and troubleshoot onsite
• Support repeat procedures

PROCEPT BioRobotics Corporation's installed base of robotic systems is a recurring revenue engine: each AquaBeam system placed creates follow-on demand for disposables, service, and support. By year-end 2021, PROCEPT BioRobotics Corporation had 130 AquaBeam systems deployed globally, including 78 in the United States.

• 130 systems deployed globally
• 78 systems in the United States
• Drives consumable and service revenue

Aquablation treats BPH across prostate sizes and shapes, with clinical use in prostates from 30 to 150 cc. That broader fit expands the hospital candidate pool and can lift system use; PROCEPT BioRobotics reported 2025 revenue of $220.1 million for the trailing year, helped by wider adoption.

• Fits more BPH anatomies
• Expands patient reach
• Supports higher system utilization

PROCEPT BioRobotics Corporation’s value proposition is anchored in potential preservation of urinary and sexual function, a key driver in BPH referrals and device choice. In FY2025, that message helped support surgeon adoption as clinicians and patients favored treatments that aim to reduce trade-offs versus TURP and other resection options.

• Preservation supports referral conversion.
• Function matters in BPH decisions.
• Better outcomes can lift surgeon preference.

Surgeon uptake at PROCEPT BioRobotics Corporation is built on evidence-based peer education: publications, conference talks, and center-of-excellence sites help urologists learn from early adopters before switching practice. That fits specialty medtech, where trust and clinical proof drive use; PROCEPT reported FY2024 revenue of about $220 million, up roughly 65% year over year.

• Peer-to-peer learning lowers adoption friction.
• Clinical data supports surgeon confidence.
• Center sites speed real-world proof.

Once a PROCEPT BioRobotics Corporation system is installed, the account can stay sticky for years because support quality shapes surgeon trust, procedure volume, and recurring consumable use. Strong field service and training matter because every retained system can keep driving repeat cartridge and service revenue.

• Retention depends on uptime and case support.

• Higher procedure volume lifts consumable pull-through.

• Poor support can slow renewals and expansions.

Urology congresses are a core awareness channel for PROCEPT BioRobotics Corporation, because peer proof matters most in procedural devices. At meetings like AUA and EAU, the company can show clinical data, train specialists, and support adoption in a market where surgeon trust drives case volume.

• Peer-reviewed data builds credibility
• Direct access to urologists and KOLs
• Supports product education and adoption

PROCEPT BioRobotics Corporation uses digital medical and corporate communications to educate buyers through web content, clinical materials, and investor updates. In fiscal 2025, revenue reached $79.5 million, and the company’s digital reach helps support lead generation, surgeon education, and visibility with stakeholders as it scales AquaBeam adoption.

• Web content supports lead generation
• Clinical materials aid surgeon education
• Investor updates improve visibility

Male patients with benign prostatic hyperplasia are the core demand pool: BPH affects about 14 million U.S. men, and lower urinary tract symptoms are the end-user need PROCEPT BioRobotics targets. Patient choice matters because men who want faster relief and to avoid repeat drugs can push physicians and hospitals toward robotic waterjet therapy.

• Core demand pool for treatment
• LUTS drives therapy choice
• Patient preference affects adoption

Outside the United States, hospitals and clinics are a key growth segment for PROCEPT BioRobotics Corporation, but each market needs local regulatory clearance, commercial coverage, and often reimbursement support. In FY2025, this made international growth slower than U.S. demand, but it can scale quickly after country-level approval and market access are secured.

• Hospitals and clinics drive ex-U.S. growth
• Approval is needed country by country
• Local sales support matters
• Reimbursement can speed adoption

Clinical, regulatory, and quality systems are a fixed-cost load for PROCEPT BioRobotics Corporation because device approvals, post-market surveillance, and ongoing clinical evidence need specialist teams, SOPs, and audit-ready documentation. In FY2025, that cost base stayed tied to regulated medtech work, not unit volume, so margin depends on spreading these overheads across growing procedure and system sales.

• Specialist regulatory and clinical staff
• Ongoing trials and documentation
• QMS and audit compliance are fixed costs
• Post-market surveillance adds steady spend

Field service and logistics are a rising cost for PROCEPT BioRobotics Corporation because each installed system needs maintenance, spare parts, software support, and fast field repairs. Shipping, calibration, and service staff also scale with the installed base, so gross support costs rise as more Aquablation systems are placed and kept uptime-ready.

• Maintenance, replacements, and technical support
• Shipping and service network for uptime
• Costs increase with installed base growth

Accessories and spare parts create recurring revenue as PROCEPT BioRobotics Corporation's installed base grows, because systems need replacement components, consumables, and service items over time. This also protects field performance by keeping each robot calibrated and working, which supports repeat demand after the initial system sale.

• Installed base drives repeat sales.
• Replacement parts support device uptime.
• Recurring mix lowers revenue volatility.

PROCEPT BioRobotics Corporation also earns revenue from markets outside the United States, where international placements can use different pricing and channel terms than U.S. sales. This global push widens the total addressable market, and in FY2025 the company continued to scale commercial reach through overseas expansion.

• Non-U.S. sales add growth upside.
• Channel terms can vary by market.
• Global reach expands TAM.